Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 8/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8421890 | 0.85 | MAPK14 (0.53) | HDAC4MAPK14SMYD3HDAC6POLB | |
| SCHEMBL8281127 | 0.83 | HDAC4 (0.49) | HDAC4MAPK14SMYD3HDAC6NPC1 | |
| SCHEMBL8221034 | 0.76 | HDAC4 (0.46) | HDAC4MAPK14SMYD3HDAC6 | |
| SCHEMBL8226263 | 0.74 | HDAC4 (0.56) | HDAC4HDAC6 | |
| SCHEMBL8221319 | 0.72 | L3MBTL1 (0.54) | NPC1RAB9AKMT2ATSHRSMN1; SMN2 | |
| SCHEMBL105413 | 0.71 | TAS1R3 (0.53) | MAPK14NPC1RAB9AKMT2AMCHR1 | |
| SCHEMBL8221535 | 0.69 | ABCB1 (0.44) | HDAC4HDAC6 | |
| SCHEMBL29082307 | 0.69 | RAB9A (0.47) | HDAC4MAPK14SMYD3HDAC6NPC1 | |
| SCHEMBL30685468 | 0.69 | RAB9A (0.47) | HDAC4MAPK14SMYD3HDAC6NPC1 | |
| SCHEMBL29082305 | 0.69 | RAB9A (0.47) | HDAC4MAPK14SMYD3HDAC6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465740-B2 | 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | HDAC4 3302/4885MAPK14 4287/4885SMYD3 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.